Search Results - "Aurora, Sheena K"

CGRP and the Trigeminal System in Migraine by Iyengar, Smriti, Johnson, Kirk W., Ossipov, Michael H., Aurora, Sheena K.

“…Objective The goal of this narrative review is to provide an overview of migraine pathophysiology, with an emphasis on the role of calcitonin gene‐related…”
Get full text

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine by Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly

“…Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled…”
Get full text

Trial of Galcanezumab in Prevention of Episodic Cluster Headache by Goadsby, Peter J, Dodick, David W, Leone, Massimo, Bardos, Jennifer N, Oakes, Tina M, Millen, Brian A, Zhou, Chunmei, Dowsett, Sherie A, Aurora, Sheena K, Ahn, Andrew H, Yang, Jyun-Yan, Conley, Robert R, Martinez, James M

“…In a trial of galcanezumab, an antibody to calcitonin gene–related peptide, for the treatment of cluster headache, a subcutaneous dose reduced the mean weekly…”
Get full text

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine by Voss, Tiffini, Lipton, Richard B, Dodick, David W, Dupre, Nicole, Ge, Joy Yang, Bachman, Robert, Assaid, Christopher, Aurora, Sheena K, Michelson, David

“…The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA),…”
Get more information

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program by Dodick, David W., Turkel, Catherine C., DeGryse, Ronald E., Aurora, Sheena K., Silberstein, Stephen D., Lipton, Richard B., Diener, Hans-Christoph, Brin, Mitchell F.

“…(Headache 2010;50:921‐936) Objective.— To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with…”
Get full text

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies by Detke, Holland C., Millen, Brian A., Zhang, Qi, Samaan, Karen, Ailani, Jessica, Dodick, David W., Aurora, Sheena K.

“…Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine. Background Galcanezumab is a monoclonal antibody that binds to…”
Get full text

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine by Hewitt, David J, Aurora, Sheena K, Dodick, David W, Goadsby, Peter J, Ge, Yang Joy, Bachman, Robert, Taraborelli, Donna, Fan, Xiaoyin, Assaid, Christopher, Lines, Christopher, Ho, Tony W

“…This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine. Multicenter, double-blind, randomized, placebo-controlled,…”
Get more information

Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial by Lipton, Richard B, MD, Dodick, David W, MD, Silberstein, Stephen D, MD, Saper, Joel R, MD, Aurora, Sheena K, MD, Pearlman, Starr H, PhD, Fischell, Robert E, ScD, Ruppel, Patricia L, MPH, Goadsby, Peter J, MD

“…Summary Background Preliminary work suggests that single-pulse transcranial magnetic stimulation (sTMS) could be effective as a treatment for migraine. We…”
Get full text

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies by Förderreuther, Stefanie, Zhang, Qi, Stauffer, Virginia L., Aurora, Sheena K., Láinez, Miguel J. A.

“…Background Maintenance of effect following treatment with galcanezumab compared to placebo in adult patients with episodic or chronic migraine was evaluated…”
Get full text

Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program by Blumenfeld, Andrew, Silberstein, Stephen D., Dodick, David W., Aurora, Sheena K., Turkel, Catherine C., Binder, William J.

“…Chronic migraine (CM) is a prevalent and disabling neurological disorder. Few prophylactic treatments for CM have been investigated. OnabotulinumtoxinA, which…”
Get full text

Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure by Tepper, Stewart J., Ailani, Jessica, Ray, Sutapa, Hirman, Joe, Shrewsbury, Stephen B., Aurora, Sheena K.

“…Background Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for…”
Get full text

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine by Ament, Michael, Day, Kathleen, Stauffer, Virginia L, Skljarevski, Vladimir, Rettiganti, Mallikarjuna, Pearlman, Eric, Aurora, Sheena K.

“…Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly…”
Get full text

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments by Kuruppu, Dulanji K, Tobin, Joshua, Dong, Yan, Aurora, Sheena K, Yunes-Medina, Laura, Green, A Laine

“…Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has…”
Get full text

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis by Matharu, Manjit, Halker, Rashmi, Pozo-Rosich, Patricia, DeGryse, Ronald, Manack Adams, Aubrey, Aurora, Sheena K.

“…Background OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine…”
Get full text

New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay by McConnachie, Lisa, Goadsby, Peter J, Vann, Robert E, Ray, Sutapa, Shrewsbury, Stephen B, Aurora, Sheena K

“…Dihydroergotamine mesylate (DHE) is an established effective acute therapy for migraine and is often characterized by its broad receptor pharmacology…”
Get full text

Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America by Jensen, Rigmor Hoejland, Tassorelli, Cristina, Myers Oakes, Tina M, Bardos, Jennifer N, Zhou, Chunmei, Dong, Yan, Aurora, Sheena K, Martinez, James M

“…Two phase 3 galcanezumab trials were conducted in Europe and North America to analyze the reduction of weekly cluster headache (CH) attack frequency in…”
Get full text

Long-Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial by Connor, Kathryn M., Aurora, Sheena K., Loeys, Tom, Ashina, Messoud, Jones, Christopher, Giezek, Hilde, Massaad, Rachid, Williams-Diaz, Angela, Lines, Christopher, Ho, Tony W.

“…(Headache 2011;51:73‐84) Objective.— To evaluate the long‐term tolerability of telcagepant for acute treatment of intermittent migraine attacks. Background.—…”
Get full text

Brainstem Dysfunction in Chronic Migraine as Evidenced by Neurophysiological and Positron Emission Tomography Studies by Aurora, Sheena K., Barrodale, Patricia M., Tipton, Reda L., Khodavirdi, Ani

“…Background.—The pathophysiology of chronic migraine (CM) is not fully understood. We aimed to examine transcranial magnetic stimulation (TMS) indices of…”
Get full text

Transcranial Magnetic Stimulation for Migraine: A Safety Review by Dodick, David W., Schembri, Carol T., Helmuth, Michele, Aurora, Sheena K.

“…(Headache 2010;50:1153‐1163) Objective.— To review potential and theoretical safety concerns of transcranial magnetic stimulation (TMS), as obtained from…”
Get full text

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine by Ament, Michael, Day, Kathleen, Stauffer, Virginia L., Skljarevski, Vladimir, Rettiganti, Mallikarjuna, Pearlman, Eric, Aurora, Sheena K.

Get full text